+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07258511

Comparing JNJ-79635322 and an Anti-BCMAxCD3 Antibody for Relapsed or Refractory Multiple Myeloma in Adults Who Have Received Multiple Prior Therapies

Led by Janssen Research & Development, LLC · Updated on 2026-11-03

400

Participants Needed

157

Research Sites

146 weeks

Total Duration

AI-Summary

What This Trial Is About

This trial investigates treatments for adults with relapsed or refractory multiple myeloma who have already received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. Researchers are comparing the effects of a new drug called JNJ-79635322 with an anti-BCMAxCD3 bispecific antibody called teclistamab. The goal is to evaluate how well JNJ-79635322 works in comparison to the existing antibody treatment. Participants will be randomly assigned to receive either JNJ-79635322 or teclistamab, both given as subcutaneous injections. Treatments will continue until the disease progresses or participants experience intolerable side effects. The study is designed as a phase 3 trial, with treatment lasting potentially up to several years depending on individual response and tolerance. During the trial, participants will have regular assessments to monitor response to treatment, disease progression, side effects, and quality of life. Measures include overall response, progression-free survival, complete response rates, symptom and functioning questionnaires, and laboratory tests. Safety is closely monitored, along with drug levels and immune responses. The total participation period may last up to five years and seven months, with ongoing evaluations throughout this time.

CONDITIONS

Brief Title

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

Research Team

S

Study Contact

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here